Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.

Donato, Veronica; Kim, Haesook T; Stowe, Peter; Reynolds, Carol G; Ritz, Jerome; Koreth, John; Whangbo, Jennifer S

Donato, Veronica; Kim, Haesook T; Stowe, Peter; Reynolds, Carol G; Ritz, Jerome; Koreth, John; Whangbo, Jennifer S.

Afiliação

Donato V; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, United States.
Kim HT; Master of Medical Sciences in Clinical Investigation Program, Harvard Medical School, Boston, MA, United States.
Stowe P; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, United States.
Reynolds CG; Harvard School of Public Health, Boston, MA, United States.
Ritz J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, United States.
Koreth J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, United States.
Whangbo JS; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, United States.

Front Immunol ; 13: 954966, 2022.

Article em En | MEDLINE | ID: mdl-36189229

Assuntos

Doença Enxerto-Hospedeiro; Transplante de Células-Tronco Hematopoéticas; Adulto; Criança; Doença Crônica; Doença Enxerto-Hospedeiro/tratamento farmacológico; Doença Enxerto-Hospedeiro/etiologia; Humanos; Interleucina-2/uso terapêutico; Esteroides/uso terapêutico

Palavras-chave

allogeneic stem cell transplantation; chronic graft vs. host disease; low-dose interleukin-2; regulatory T cells; steroid refractory graft versus host disease

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google